If you’re seeking perfect vision, you may be interested in the Ocumetics Bionic Lens. The future holds much for those who struggle to see clearly with this lens. Dr. Garth Webb who is from Ocumetics Technology Corp. has helped to develop this lens and it will be changing millions of lives for the better.

 

New Bionic Lens Promises Perfect Vision For Lifetime_Image 0

Image Source: Ocumetics Technology Corp

 According to Bionic lens makers, it impacts and enhances eyesight beyond the normal scope of 20/20 vision. Painless to implant, it enables the wearer to see up to three times as well as without. Thus, they can experience a higher quality vision.

 

New Bionic Lens Promises Perfect Vision For Lifetime_Image 1

Image Source: Ocumetics Technology Corp/ Canadian Press

Researchers spent eight years studying eyesight and they spent $3 million coming up with the Ocumetic design. Webb is optimistic regarding the results of the Ocumetic bionic Lens and it’s an eight-minute procedure.

 

New Bionic Lens Promises Perfect Vision For Lifetime_Image 4

Image Source: Ocumetics Technology Corp

New Bionic Lens Promises Perfect Vision For Lifetime_Image 2Ocumetic Bionic Lens isn’t designed as a contact lens. It actually adheres to the biconvex lens in the eye. The bionic lens insertion is easy and can be done as an outpatient.

 

New Bionic Lens Promises Perfect Vision For Lifetime_Image 2

Image Source: Ocumetics Technology Corp

The procedure is simple. Some saline solution with the bionic lens is flushed into the eye with a syringe. The lens, which is folded, opens up and sticks to the natural lens within ten seconds. The patient will notice a visible difference as soon as the lens is inserted. They will be able to see farther and clearer in seconds.

 

Bionic Lens

Image Source: Ocumetics Technology Corp

Ocumetic Bionic Lens provides cataract protection as well as enhancing the natural lens in the eye. Using the saline flush procedure is safe and far less dangerous than laser methods for visual correction.

Webb is conducting more clinical trials and hopes this will be on the market by the end of 2017.